Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
708 (USA) · Dr. Kim
consented 2013-02-09
AEs
1
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Moderate APPLICATION SITE VESICLES — outcome: RECOVERED/RESOLVED; onset 2013-02-26 (study day 18.0); relationship: PROBABLE
Data queries
No data queries.